Long‐term disease control and survival observed after stereotactic ablative body radiotherapy for oligometastatic breast cancer

We examined the characteristics of breast cancer patients with oligometastases (OM) treated with stereotactic ablative body radiotherapy (SABR) to identify factors associated with local progression, distant metastasis progression, time to subsequent therapy, progression-free survival (PFS), and overall survival (OS).We retrospectively reviewed a single-institution database of patients treated with radiotherapy between 2008 and 2018 and...